Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoma

First Posted Date: 2004-08-04

Last Posted Date: 2015-08-19

Lead Sponsor: Hoag Memorial Hospital Presbyterian

Registration Number: NCT00003605

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
Bloomington Hospital, Bloomington, Indiana, United States
🇺🇸
St. Joseph Regional Cancer Center, Bryan, Texas, United States

Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Phase 3

Terminated

Conditions: Lymphoma

First Posted Date: 2004-08-02

Last Posted Date: 2012-07-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 469

Registration Number: NCT00003152

Locations: 🇳🇱
Academisch Ziekenhuis Utrecht, Utrecht, Netherlands
🇬🇧
Addenbrooke's NHS Trust, Cambridge, England, United Kingdom

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Drug/Agent Toxicity by Tissue/Organ

First Posted Date: 2004-08-02

Last Posted Date: 2013-01-31

Lead Sponsor: University of Arizona

Target Recruit Count: 30

Registration Number: NCT00003068

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

First Posted Date: 2004-08-02

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 300

Registration Number: NCT00003214

Locations: 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Klinik Hirslanden, Zurich, Switzerland
🇨🇭
City Hospital Triemli, Zurich, Switzerland

and more 7 locations

Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-30

Last Posted Date: 2014-05-22

Lead Sponsor: University of Southern California

Target Recruit Count: 46

Registration Number: NCT00003050

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
Neutropenia
Thrombocytopenia

First Posted Date: 2004-07-29

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 50

Registration Number: NCT00002665

Locations: 🇺🇸
CCOP - Dayton, Kettering, Ohio, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

and more 80 locations

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: CMF regimen
Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: mesna
Drug: epirubicin hydrochloride
Drug: fluorouracil
Procedure: peripheral blood stem cell transplantation
Drug: methotrexate
Drug: tamoxifen citrate
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-07-29

Last Posted Date: 2013-04-04

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 344

Registration Number: NCT00002784

Locations: 🇦🇺
Queen Elizabeth Hospital, Adelaide, South Australia, Australia
🇦🇺
Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 8 locations

Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: epirubicin hydrochloride
Drug: tamoxifen citrate
Drug: toremifene

First Posted Date: 2004-07-29

Last Posted Date: 2013-04-04

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 452

Registration Number: NCT00002529

Locations: 🇨🇭
Universitaetsspital, Zurich, Switzerland
🇦🇺
Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 17 locations